Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study

• DOI: 10.1111/head.14259
• Publication Date: 2022-01-25T13:18:35Z
• Authors: Richard B. Lipton; Robert A. Nicholson; Michael L. Reed; Andre B. Araujo; Dena H. Jaffe; Douglas E. Faries; Dawn C. Buse; Robert E. Shapiro; Sait Ashina; M. Janelle Cambro...; John C. Rowland; Eric M. Pearlman
• Keywords: Migraine treatment

The ObserVational survey of the Epidemiology, tReatment and Care MigrainE (OVERCOME; United States) study is a multicohort, longitudinal web that assesses symptomatology, consulting, diagnosis, treatment, impact migraine in States.Regularly updating population-based views States provides method for assessing quality ongoing care identifying unmet needs.The OVERCOME (US) 2018 cohort involved: (I) creating demographically representative sample US adults using quota sampling (n = 97,478), (II) people with active past year via validated diagnostic questionnaire and/or self-reported medical diagnosis 24,272), (III) consultation, treatment 21,143). current manuscript evaluated whether those low frequency episodic (LFEM; 0-3 monthly headache days) differed from other categories on outcomes interest.Among 21,143), 19,888 (94.1%) met our International Classification Headache Disorders, 3rd edition-based case definition 12,905 (61.0%) migraine. Respondents' mean (SD) age was 42.2 (15.0) years; 15,697 (74.2%) were women. Having at least moderate disability common 8965; 42.4%) around half 10,783; 51.0%) had consulted professional year. Only 4792 (22.7%) respondents currently triptan. Overall, 8539 (40.4%) eligible preventive medication 3555 (16.8%) medication. Those LFEM high chronic nearly all measures treatment.The revealed slow but steady progress However, despite significant among population, many have needs related to consulting migraine, getting potentially beneficial treatment. Moreover, it demonstrated heterogeneity varying within